Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?
Zakrzewicz A, Würth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S, Andersen JT, Haard H, Verheesen P, Bobkov V, Tikkanen R. Zakrzewicz A, et al. Among authors: verheesen p. Cells. 2022 Mar 10;11(6):942. doi: 10.3390/cells11060942. Cells. 2022. PMID: 35326398 Free PMC article.
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N. Ulrichts P, et al. Among authors: verheesen p. J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24. J Clin Invest. 2018. PMID: 30040076 Free PMC article. Clinical Trial.
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.
Goebeler M, Bata-Csörgő Z, De Simone C, Didona B, Remenyik E, Reznichenko N, Stoevesandt J, Ward ES, Parys W, de Haard H, Dupuy P, Verheesen P, Schmidt E, Joly P; ARGX-113-1701 Investigator Study Group. Goebeler M, et al. Among authors: verheesen p. Br J Dermatol. 2022 Mar;186(3):429-439. doi: 10.1111/bjd.20782. Epub 2021 Nov 28. Br J Dermatol. 2022. PMID: 34608631 Clinical Trial.
Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942.
Zakrzewicz A, Würth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S, Andersen JT, Haard H, Verheesen P, Bobkov V, Tikkanen R. Zakrzewicz A, et al. Among authors: verheesen p. Cells. 2022 May 20;11(10):1700. doi: 10.3390/cells11101700. Cells. 2022. PMID: 35626757 Free PMC article.
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.
Maho-Vaillant M, Sips M, Golinski ML, Vidarsson G, Goebeler M, Stoevesandt J, Bata-Csörgő Z, Balbino B, Verheesen P, Joly P, Hertl M, Calbo S. Maho-Vaillant M, et al. Among authors: verheesen p. Front Immunol. 2022 May 18;13:863095. doi: 10.3389/fimmu.2022.863095. eCollection 2022. Front Immunol. 2022. PMID: 35663943 Free PMC article. Clinical Trial.
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement.
Brinkhaus M, Pannecoucke E, van der Kooi EJ, Bentlage AEH, Derksen NIL, Andries J, Balbino B, Sips M, Ulrichts P, Verheesen P, de Haard H, Rispens T, Savvides SN, Vidarsson G. Brinkhaus M, et al. Among authors: verheesen p. Nat Commun. 2022 Oct 14;13(1):6073. doi: 10.1038/s41467-022-33764-1. Nat Commun. 2022. PMID: 36241613 Free PMC article.
Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.
Pigors M, Patzelt S, Reichhelm N, Dworschak J, Khil'chenko S, Emtenani S, Bieber K, Hofrichter M, Kamaguchi M, Goletz S, Köhl G, Köhl J, Komorowski L, Probst C, Vanderheyden K, Balbino B, Ludwig RJ, Verheesen P, Schmidt E. Pigors M, et al. Among authors: verheesen p. J Pathol. 2024 Feb;262(2):161-174. doi: 10.1002/path.6220. Epub 2023 Nov 6. J Pathol. 2024. PMID: 37929639
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Aftimos P, Rolfo C, Rottey S, Barthélémy P, Borg C, Park K, Oh DY, Kim SW, De Jonge N, Hanssens V, Zwanenpoel K, Molthoff C, Vugts D, Dreier T, Verheesen P, van Dongen GAMS, Jacobs J, Van Rompaey L, Hultberg A, Michieli P, Pauwels P, Fung S, Thibault A, de Haard H, Leupin N, Awada A. Aftimos P, et al. Among authors: verheesen p. Biomedicines. 2021 Jun 10;9(6):665. doi: 10.3390/biomedicines9060665. Biomedicines. 2021. PMID: 34200749 Free PMC article.
28 results